Literature DB >> 15901745

Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury.

David W Wright1, James C Ritchie, Richard E Mullins, Arthur L Kellermann, Donald D Denson.   

Abstract

Progesterone (PG) has been shown to provide substantial neuroprotection after traumatic brain injury (TBI) in multiple animal models. As a first step in assessing applicability to humans, the authors examined the effects of acute TBI and extracranial trauma on the pharmacokinetics of PG given by intravenous infusion. Multiple blood samples were obtained from 11 female and 21 male trauma patients receiving PG and 1 female and 3 male patients receiving placebo infusions for 72 hours. Values for C(SS), CL, t(1/2), and Vd were obtained using AUC((0-72)) and postinfusion blood samples. C(SS) values were 337 +/- 135 ng/mL, which were significantly lower than the target concentration of 450 +/- 100 ng/mL. The lower C(SS) is attributed to the CL, which was higher than anticipated. In addition, t(1/2) was longer and V(d) was higher than anticipated. These results demonstrate that stable PG concentrations can be rapidly achieved following TBI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901745     DOI: 10.1177/0091270005276201

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  17 in total

1.  The effect of progesterone dose on gene expression after traumatic brain injury.

Authors:  Gail D Anderson; Federico M Farin; Theo K Bammler; Richard P Beyer; Alicia A Swan; Hui-Wen Wilkerson; Eric D Kantor; Michael R Hoane
Journal:  J Neurotrauma       Date:  2011-09-08       Impact factor: 5.269

2.  Combination Therapies for Traumatic Brain Injury: Retrospective Considerations.

Authors:  Susan Margulies; Gail Anderson; Fahim Atif; Jerome Badaut; Robert Clark; Philip Empey; Maria Guseva; Michael Hoane; Jimmy Huh; Jim Pauly; Ramesh Raghupathi; Stephen Scheff; Donald Stein; Huiling Tang; Mona Hicks
Journal:  J Neurotrauma       Date:  2015-08-06       Impact factor: 5.269

3.  A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury.

Authors:  Todd C Peterson; Michael R Hoane; Keith S McConomy; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Gail D Anderson
Journal:  J Neurotrauma       Date:  2015-02-26       Impact factor: 5.269

4.  Acute serum hormone levels: characterization and prognosis after severe traumatic brain injury.

Authors:  Amy K Wagner; Emily H McCullough; Christian Niyonkuru; Haishin Ozawa; Tammy L Loucks; Julie A Dobos; Christopher A Brett; Martina Santarsieri; C Edward Dixon; Sarah L Berga; Anthony Fabio
Journal:  J Neurotrauma       Date:  2011-06-01       Impact factor: 5.269

5.  Progesterone blocks multiple routes of ion flux.

Authors:  Brooke G Kelley; Paul G Mermelstein
Journal:  Mol Cell Neurosci       Date:  2011-07-19       Impact factor: 4.314

6.  Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice.

Authors:  Denise Harhausen; Uldus Khojasteh; Philip F Stahel; B Paul Morgan; Wilfried Nietfeld; Ulrich Dirnagl; George Trendelenburg
Journal:  J Neuroinflammation       Date:  2010-03-04       Impact factor: 8.322

Review 7.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

Review 8.  Gender and the injured brain.

Authors:  Kamila Vagnerova; Ines P Koerner; Patricia D Hurn
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

Review 9.  Progesterone for acute traumatic brain injury.

Authors:  Junpeng Ma; Siqing Huang; Shu Qin; Chao You; Yunhui Zeng
Journal:  Cochrane Database Syst Rev       Date:  2016-12-22

10.  Estriol and progesterone: a new role for sex hormones.

Authors:  Sanja Draca
Journal:  Int J Biomed Sci       Date:  2006-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.